17-20 SEPTEMBER 2023 | VALENCIA
Influenza
RSV Disease
Covid-19

Conference Schedule

Sunday 17 September 2023
09:30 - 18:00
Registration desk openreg01
Exhibition hall
11:00 - 12:30
The bidirectional relationship between influenza and diabetes mellitus: how can we improve health through better flu immunisation?sps01
Auditorium 3 - Breakout
Chair
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands

Introduction

Dr. Marco Goeijenbier, Spaarne Hospitaal, ESWI Member, chair IDC

Round 1: Why influenza and diabetes specifically? The evidence for severe influenza in persons living with diabetes.

Dr. Kirsty Short, ESWI Associate member, University of Queensland, Australia

Dr. Felix Wensveen, Rijeka University, Croatia

Round 2: Is there a bidrectional relationship between influenza and diabetes? 

Dr. Katina Hulme, Amsterdam UMC, The Netherlands

Dr. Rik Endeman, Erasmus University Rotterdam, The Netherlands

Dr. Marco Goeijenbier, Spaarne Hospitaal, ESWI Member, chair IDC

Round 3: What role does influenza virus vaccination play in diabetes progression or even occurrence?

Prof. Mads Kjølby, Aarhus University, Denmark

Round 4: How can we improve Vaccination uptake in the consulting room

Dr. Wesley de Jong, Erasmus MC, The Netherlands

Prof. Joao Filipe Raposo, IDF Europe Board Member, and Medical Director for the Associação Protectora dos Diabéticos de Portugal (APDP)

Round table discussion 

Dr. Marco Goeijenbier, Spaarne Hospitaal, ESWI Member, chair IDC

Dr. Katina Hulme, Amsterdam UMC, The Netherlands

Dr. Rik Endeman, Erasmus University Rotterdam, The Netherlands

Dr. Kirsty Short, ESWI Associate member, University of Queensland, Australia

Dr. Felix Wensveen, Rijeka University, Croatia

Prof. Mads Kjølby, Aarhus University, Denmark

Dr. Wesley de JongErasmus MC, The Netherlands

Prof. Joao Filipe RaposoIDF Europe Board Member, and Medical Director for the Associação Protectora dos Diabéticos de Portugal (APDP)

------

This session is organised by ESWI and the Influenza Diabetes Community. Made possible thanks to IFPMA.

12:30 - 13:15
Lunchql01
Exhibition hall
13:15 - 14:45
The high burden of RSV and influenza: Beyond the acute infection in adults - Satellite Symposium organised by Medscapesat01
Auditorium 1 - Plenary Hall
Chair
Peter Openshaw
Peter Openshaw, ESWI Board Member, Imperial College, The United Kingdom

Introduction
Peter Openshaw, ESWI Board member, Imperial College London, United Kingdom

It Could Be You: The Unheard Voices of RSV and Influenza From a Specialist Perspective
Panel discussion with Marco Goeijenbier, Krzysztof Narkiewicz and David B Price

Case Series to Identify Who Is at Risk of Chronic Complications and Why We Should Think Beyond Just the Acute Infection
Panel discussion with Marco Goeijenbier, Krzysztof Narkiewicz and David B Price

Unmet Needs in the Management of Respiratory Viral Diseases and Emerging Vaccine Strategies
Panel discussion with Marco Goeijenbier, Krzysztof Narkiewicz and David B Price

Closing Remarks and Q&A
Peter Openshaw, ESWI Board member, Imperial College London, United Kingdom

15:00 - 16:30
How quality evidence and modern research infrastructure can help us to fight against influenza and its complications? - Satellite Symposium organised by Sanofisat02
Auditorium 1 - Plenary Hall
Chairs
Ivan Sanz-Muñoz
Ivan Sanz-Muñoz, Hospital Clínico Universitario de Valladolid, Spain
Ralf Dechend
Ralf Dechend, Ag Müller/dechend Experimental And Clinical Research Center (ecrc), Germany
Lectures
Co-Chairman introduction with Ralf Dechend and Iván Sanz Muñoz
Ivan Sanz-Muñoz, Hospital Clínico Universitario de Valladolid, Spain
Influenza Vaccine and Quality of Data: Impacts of Study Design and Endpoints
Stefania Maggi, National Research Council of Italy, Italy
Using a Pragmatic Randomized Trial to Assess the Relative Effectiveness of Influenza Vaccine
Tor Biering-Sørensen, Herlev And Gentofte Hospital, Denmark
The Impact of Increasing Vaccination Coverage Rate at the same time as Quality of Evidence
Fiona Ecarnot, Chu Besançon, France
Discussion and Q&A with all faculty members
Ralf Dechend, Ag Müller/dechend Experimental And Clinical Research Center (ecrc), Germany
16:30 - 17:00
Coffee Breakcof06
Exhibition hall
17:00 - 18:00
Plenary Openingple01
Auditorium 1 - Plenary Hall
Chairs
Ab Osterhaus
Ab Osterhaus, ESWI Chair, TiHO, Germany
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands

A welcome word from the Conference Chairs

Ab Osterhaus, ESWI Chair, TiHo, Germany

Colin Russell, ESWI Board Member, Academic Medical Center, The Netherlands

Marco Goeijenbier, ESWI Board Member, Spaarne Gasthuis,The Netherlands

Passing the baton: Introducing ESWI's new Executive Committee

Ab Osterhaus, ESWI Chair, TiHo, Germany

Colin Russell, ESWI Board Member, Academic Medical Center, The Netherlands

Marco GoeijenbierESWI Board Member, Spaarne Gasthuis,The Netherlands

Ted van Essen, ESWI Board Member, The Netherlands

Stefania MaggiESWI Board Member, National Research Council of Italy, Italy

Scientific Keynote: “Immune Responses to Respiratory Viruses and ‘Long-Haul’ Disease” 

Peter Openshaw, ESWI Board Member, Imperial College London, United Kingdom 

Launch of the ESWI Early Career Scientists Community 

Debby Van Riel, Erasmus MC, The Netherlands 

18:00 - 20:00
Welcome networking eveningrec01
Exhibition hall
20:00 - 21:00
Poster Sneak Previewpos01
Poster Exhibit
21:00 - 23:00
Early Career Scientists networking evening - Invitation Onlyyse01
Monday 18 September 2023
08:00 - 09:00
Boosting Influenza Vaccination: Increasing vaccine uptake to optimize care and budget - Satellite Symposium organised by Viatrissat03
Auditorium 1 - Plenary Hall
Chair
Ted Van Essen
Ted Van Essen, Retired General Practitioner and vocational trainer, Amersfoort, The Netherlands
Lectures
Introduction on the topic of Boosting Influenza Vaccination: Increasing Vaccine uptake to optimize care and Budget
Ted van Essen, ESWI, The Netherlands
Budget impact of a high-dose influenza vaccine compared to standard vaccines in the older German population
Juergen Wasem, University Duisburg-Essen, Germany
Budget impact of a high-dose influenza vaccine compared to standard vaccines in the older German population
Christian Speckemeier, EsFoMed GmbH, Germany
Increasing vaccination rates to optimize care
Marc Van Ranst, University of Leuven, Belgium
Panel discussion and closing remarks
Ted van Essen, ESWI, The Netherlands
09:15 - 10:15
Plenary Session: Keynote lecturesple02
Auditorium 1 - Plenary Hall
Chair
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands
Lectures
Human immunity in respiratory virus infection and vaccination
Katherine Kedzierska, University of Melbourne, Australia
What science tells us about the origin and emergence of COVID-19
Edward Holmes, University of Sydney, Australia
10:15 - 10:45
Coffee Breakcof01
Exhibition hall
Poster Peek - Virtualpeek01
Poster Peak - web platform
Chair
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands

Increasing HbA1c is associated with reduced CD8+ T cell functionality in response to influenza virus in a TCR-dependent manner in individuals with diabetes mellitus
Katina Hulme, Amsterdam UMC, Netherlands

Severity of 1st, 2nd, and 3rd SARS-CoV-2 infections
Aubree Gordon, University of Michigan, United States of America

Cost-effectiveness of reduced viral transmission with baloxavir antiviral treatment for seasonal and pandemic influenza in the United Kingdom
Hassan Zaraket, Roche Products Ltd, United Kingdom

RSV and other respiratory viruses in older adults with ARI in the outpatient setting in Germany in the 2022/23 season
Alan Marijam, GSK, Belgium

10:45 - 12:20
Parallel sessions
Epidemiology, (sero)surveillance, including virus evolution and strain selectionscs01
Auditorium 1 - Plenary Hall
SCS
Chairs
John Paget
John Paget, ESWI Associate Member, Nivel, The Netherlands
Nathan Brendish
Nathan Brendish, University of Southhampton, United Kingdom, The United Kingdom
Lectures
Assessment of the dynamic change of population immunity and susceptibility to emerging influenza antigenic variants in the United States
Min Levine, Influenza Division, Centers for Disease Control and Prevention, United States of America
Influenza B Virus Neuraminidase: Antigenic evolution and antibody responses
Thi Hoai Thu Do, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute of Infection and Immunity, Melbourne, Australia
RSV-F Protein Evolution: Antigenic Escape on the horizon?
Lucy Mosscrop, Imperial College London, United Kingdom
Genetic and antigenic evolution of the Influenza B virus haemagglutinin over 81 years
Lara Schwab, Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
Nationwide SARS-CoV-2 seroprevalence trends among subgroups in the Netherlands in the Variant of Concern era, 2021-2022: an ongoing prospective cohort study
Eric R.A. Vos, National Institute for Public Health and the Environment (RIVM), Netherlands, The
Virus and host factors in pathogenesis - part 1scs02
Auditorium 2 - Breakout
SCS
Chairs
Sebastian Beck
Sebastian Beck, Leibniz-Institut für Virologie (LIV), Germany
Kirsty Short
Kirsty Short, ESWI Associate Member, University of Queensland, Australia
Lectures
High expression of oleoyl-ACP-hydrolase during early influenza infection defines severe and fatal disease outcomes
Katherine Kedzierska, Department of Microbiology & Immunology, University of Melbourne, at Peter Doherty Institute, Melbourne, Australia
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
Sebastian Beck, Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, Hamburg, Germany
Perturbed immune responses towards influenza virus following arbovirus co-infection lead to exacerbated respiratory disease severity
Lukasz Kedzierski, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
UFMylation impacts the replication of influenza A virus
Rocio Seoane, Icahn School of Medicine at Mount Sinai, New York, USA
Mechanisms and consequences of co-infections with SARS-CoV-2 and influenza virus
Dorothee Reuss, Imperial College London, United Kingdom
Why influenza and RSV disease are a priority for policy makersspi01
Auditorium 3 - Breakout
SPI
Chair
Hanna Nohynek
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
Lectures
Introduction
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
How transparent rules of collaboration enable public-private partnerships can benefit the EU research and health ecosystem
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
How evidence generated through European collaborative efforts have helped defining the RSV burden and preparing RSV surveillance in Europe
Eeva Bromberg, ECDC, Sweden
Importance of surveillance and need for data to monitor flu vaccination rates
George Kassianos, Royal College of General Practitioners, United Kingdom
Cost-effectiveness of monoclonal antibody and maternal immunisation against RSV
Xiao Li, University of Antwerp, Belgium
Panel on flu and RSV immunisation recommendations from a country perspective, with George Kassianos and Javier Diez-Domingo
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
12:30 - 13:10
On the front line: intranasal vaccine technology in the prevention of childhood influenza - Satellite Symposia organised by AstraZenecasat04
Auditorium 1 - Plenary Hall
Chair
Peter Openshaw
Peter Openshaw, ESWI Board Member, Imperial College, The United Kingdom
Lectures
The first frontier: mucosal immunity and its role in the response to respiratory infections
Peter Openshaw, Imperial College London, ESWI Board Member, United Kingdom
From theory to practice: real-world effectiveness and experience with LAIV
Terho Heikkinen, University of Turku, Finland, Finland
Discussion and Q&A with all presenters
Peter Openshaw, Imperial College London, ESWI Board Member, United Kingdom
12:30 - 14:00
Lunchlun01
Exhibition hall
13:20 - 14:00
Endemic but not the end: the continued burden of COVID-19 in immunocompromised populations - Satellite Symposia organised by AstraZenecasat04
Auditorium 1 - Plenary Hall
Chair
Andrew Ustianowski
Andrew Ustianowski, National Institute for National Health and Care Research, The United Kingdom
Lectures
Staying informed in the endemic era
Andrew Ustianowski, National Institute for National Health and Care Research, United Kingdom
Building a future for all
Roger Paredes, IrsiCaixa AIDS Research Institute, Spain
Discussion and Q&A with all presenters
Andrew Ustianowski, National Institute for National Health and Care Research, United Kingdom
14:10 - 15:45
Parallel sessions
Science based preparedness for and management of epidemics and pandemicsscs03
Auditorium 2 - Breakout
SCS
Chair
Peter Openshaw
Peter Openshaw, ESWI Board Member, Imperial College, The United Kingdom
Lectures
Preparedness and resilience for emerging threats: development of operational tools and networks for national pandemic preparedness for respiratory pathogens
Isabel Bergeri, World Health Organization HQ, Geneva, Switzerland
Modelling the public health and economic benefits of early versus late vaccination in a pandemic situation in the US: the influenza case study
Van Hung Nguyen, VHN Consulting, France
WHO’s Unity Studies: a global preparedness and readiness framework of investigations and studies of emerging respiratory pathogens of pandemic potential to inform evidence-based action
Nicki L Boddington, Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland
Establishing thresholds for the severity of influenza epidemics in Hong Kong
Jessica Y. Wong, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
Development of Self- amplifying mRNA Influenza pandemic Vaccines
Cheng Chang, CSL
Innate and adaptive immunityscs04
Auditorium 1 - Plenary Hall
SCS
Chairs
Guus  Rimmelzwaan
Guus Rimmelzwaan, University of Veterinary Medicine, Research Center for Emerging Infections and Zoonoses, Germany, Germany
Carolien van de Sandt
Carolien van de Sandt, The University of Melbourne at the Peter Doherty Institute, Australia
Lectures
Bifurcated trajectory of influenza-specific CD8+ T cells across the human lifespan stems from newborn/child-like molecular signatures in the elderly
Carolien van de Sandt, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Influenza and SARS-CoV-2 virus infection and vaccination relies on a network of T cell and B cell immunity
Oanh Nguyen, University of Melbourne, Australia
Release of influenza A virus vRNPs by macrophages during abortive infection shapes innate immune response
Svenja Fritzlar, Department of Microbiology and Immunology, University of Melbourne, Melbourne VIC Australia
Modeling asymmetric immunity elicited by influenza B viruses in ferrets
Stephen Mark Tompkins, University of Georgia, Athens, GA, USA; Center for Influenza Disease and Emergence Research, Athens, GA, USA
Acute and convalescent Immune dynamics during Influenza A infection in hospitalized patients
Kristin Greve-Isdahl Mohn, Influensa Centre, Departemen of Clinical Sciences, University of Bergen, Norway, Norway; Departement of Medicine, Haukeland Universtity Hospital, Bergen, Norway
Future vaccination strategies: Science meets policyscs17
Auditorium 3 - Breakout
SCS
Chairs
Ab Osterhaus
Ab Osterhaus, ESWI Chair, TiHO, Germany
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands
Lectures
Intranasal seasonal influenza vaccine (FluGEM) adjuvanted with bacterial particles: a phase I, randomized, double-blind, controlled, dose-ascending study.
Johan L. Van Der Plas, Centre for Human Drug Research (CHDR), Netherlands, The; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
Development and application of a next-generation single-dose mucosal COVID-19 vaccine
Michael D'Agostino, McMaster University, Canada
A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets
Jørgen de Jonge, Centre for Infectious Disease Control, National Institute for Public Health and the Environ-ment (RIVM); Bilthoven, the Netherlands
Safety and Immunogenicity of mRNA-based Seasonal Influenza Vaccines Including Hemagglutinin and Neuraminidase Antigens in Adults
Jintanat Ananworanich, Moderna, Inc., Cambridge, MA, United States of America
Age-dependent induction of stalk-reactive antibodies with ADCC reporter activity by administration of a live-attenuated influenza virus vaccine to children
Juan Manuel Carreno Quiroz, Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA
15:45 - 16:15
Coffee Breakcof02
Exhibition hall
Poster Peek - Virtualpeek02
Poster Peak - web platform
Chair
Paula Tähtinen
Paula Tähtinen, ESWI Board Member, University of Turku, Finland

Uptake of the Live Attenuated Influenza Vaccine (LAIV) in children during the 2013 to 2021 flu seasons in England: a retrospective observational study using CPRD-HES data
Christine Masters, AstraZeneca, United Kingdom

RSV epidemiology and health care resource use associated with RSV patients in inpatient care in Switzerland 2016-2021
Michael StuckiZHAW Zurich University of Applied Sciences, Switserland

Infants not exposed to bronchioloitis during the 2020 lockdown present a reduction of subsequent wheezing illnesses: a population database analyses
Riccardo Boracchini, University of Milano-Bicocca, Italy

16:15 - 17:50
Parallel sessions
Diagnosis and diagnostics in ARVIscs05
Auditorium 2 - Breakout
SCS
Chairs
Pieter Fraaij
Pieter Fraaij, Erasmus MC, The Netherlands
Corine Geurts van Kessel
Corine Geurts van Kessel, Erasmus MC, The Netherlands
Lectures
Point-of-care testing for antiviral host response using FebriDx MxA continues to be an accurate and useful Emergency Department triage tool in the context of co-circulation of Influenza, SARS-CoV-2, and RSV
Nathan Brendish, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, UK
Distinguishing influenza A subtypes with a one-step, multiplex real-time RT-PCR assay
Marie Kirby, CDC, United States of America
Effect of slow evolutionary changes in SARS-CoV-2 nucleocapsid protein on its antigenic and immunogenic properties
Alexandra Rak, Institute of Experimental Medicine, Russian Federation
Host transcriptome profiling to predict severity of acute respiratory infections
Cosimo Cristella, Amsterdam UMC, The Netherlands
Infectivity of the diagnosis of ARVI
Pieter Fraaij, Erasmus MC, The Netherlands
Virus and host factors in pathogenesis - part 2scs06
Auditorium 1 - Plenary Hall
SCS
Chairs
Adolfo García-Sastre
Adolfo García-Sastre, Icahn School of Medicine Mount Sinai, United States of America
Louise Rowntree
Louise Rowntree, University of Melbourne, Australia
Lectures
A novel influenza A virus HA subtype discovered in wild diving ducks exhibits MHC class II receptor specificity
Umut Karakus, Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA
Modeling Immunity: Defining integrated drivers of immune variation and utilizing basal immune profiles as predictors of disease susceptibility
Aisha Souquette, St. Jude Children's Research Hospital, Memphis, TN, USA; University of Tennessee Health Science Center, Memphis, TN, USA
Small molecule inhibitors of myc pathway impedes influenza a virus replication through not c-myc but max protein dependent mechanism
Soner Yildiz, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, USA
From Pandemics Past to Present: Unveiling the Role of TMPRSS2 in the Proteolytic Activation of Pandemic and Zoonotic Influenza- and Coronaviruses in Human Airway Cells
Marie Schwerdtner, Institute of Virology, Philipps-University Marburg, Marburg, Germany
ACE2 increases TMPRSS2 activity and is involved in influenza A virus hemagglutinin cleavage in human airway cells
Miriam Ruth Heindl, Institute for Virology, Philipps University Marburg, Germany
Best practices in vaccination programmes for risk groups and healthcare workersspi03
Auditorium 3 - Breakout
SPI
Chair
Barbara Rath
Barbara Rath, Vaccine Safety Initiative, Germany
Lectures
Best practices on improving vaccination uptake in hard to reach populations, the European perspective
Barbara Rath, Vaccine Safety Initiative, Germany
Best practices in forming multi-stakeholder immunisation coalitions, the USA perspective
Litjen (L.J.) Tan, Immunize.org, United States of America
Immunisation coalitions in LMIC's
Marissa Malchione, Sabin Vaccine Institute, United States of America
The Spanish immunisation coalition: our path forwards
Jaime Jesús Pérez Martín, Dirección General de Salud Pública y Adicciones, Spain
Audience debate
Barbara Rath, Vaccine Safety Initiative, Germany
18:00 - 19:30
Going Viral: Dealing with Evolving Respiratory Viruses Post-Pandemic? - Satellite Symposium organised by BioNTechsat05
Auditorium 1 - Plenary Hall
Lectures
Welcome and Introduction
Kristin Greve-Isdahl Mohn, University of Bergen, Norway, Norway
A vision for a future with a reduced threat from respiratory viruses
Kristin Greve-Isdahl Mohn, University of Bergen, Norway, Norway
How has COVID-19 impacted the epidemiological landscape of seasonal respiratory viral infections?
Ben Cowling, University of Hong Kong, Hong Kong S.A.R. (China)
The role of T cell responses in prevention of disease associated with respiratory viral infections
Louise Rowntree, University of Melbourne, Australia
Panel discussion and Q&A with all faculty
Kristin Greve-Isdahl Mohn, University of Bergen, Norway, Norway
19:30 - 21:00
Poster Networking Sessionpos02
Poster Exhibit
Tuesday 19 September 2023
07:45 - 08:30
How Much Respiratory Viral Genome Sequencing Do We Need? - Special Partner Session organised by ISIRVsps02
Auditorium 1 - Plenary Hall
Chair
Maria Zambon
Maria Zambon, UKHSA, The United Kingdom
Lectures
SARS CoV 2
John Paget, Nivel, ESWI Associate Member, The Netherlands
Influenza
John McCauley, The Francis Crick Institute, United Kingdom
RSV
Fernando Couto Motta, WHO / Instituto Oswaldo Cruz, Brazil, Brazil
08:40 - 09:00
Company lecture organised by Sanoficom01
Auditorium 1 - Plenary Hall
Lecture
What makes a Good Influenza Vaccine?
Raul Gomila, Vaccines R&d, United States of America
09:15 - 10:15
Plenary Session: Keynote lecturesple03
Auditorium 1 - Plenary Hall
Chair
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands
Lectures
Controlled Human Infection Models: a talk with Adrian Wildfire
Christopher Chiu, Imperial College London, United Kingdom
Controlled Human Infection Models: a talk with Christopher Chiu
Adrian Wildfire, CHIMunomics, United Kingdom
High-risk populations and Influenza
Stacey Schultz-Cherry, St. Jude Children's Research Hospital, United States of America
10:15 - 10:45
Coffee Breakcof03
Exhibition hall
Poster Peek - Virtualpeek03
Poster Peak - web platform
Chair
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands

Repeat vaccination with recombinant or cell-based influenza vaccines in healthcare personnel redirected antibody responses from egg-adapted epitopes in the hemagglutinin of A(H3N2) influenza virus
Feng Liu, Centers for Disease Control and Prevention, United States of America

Genomic monitoring of SARS-CoV-2 variants using sentinel SARI hospital surveillance
Sarah Denayer, Sciensano, Belgium

Burden of respiratory syncytial virus (RSV) disease in older adults with acute respiratory infection (ARI) in Europe during the 2021/2022 season
Sílvia Narejos Pérez, CAP CENTELLES, Spain

10:45 - 12:20
Parallel sessions
Pharmaceutical and non pharmaceutical interventionscs07
Auditorium 1 - Plenary Hall
SCS
Chair
Ben Cowling
Ben Cowling, University of Hong Kong, Hong Kong
Lectures
Preliminary findings from a randomized placebo-controlled trial of repeat influenza vaccination (the DRIVE study)
Ben Cowling, University of Hong Kong, Hong Kong S.A.R. (China)
Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States
Alicia N. Stein, CSL Seqirus, Australia
Is precautionary health behavior a confounder for COVID-19 vaccine effectiveness estimates? A COVIDRIVE post-hoc analysis
Sanskruti Gaikwad, P95 Pharmacovigilance and Epidemiology - Leuven (Belgium)
DRIVEN Study: quaDRivalent Influenza Vaccines patient description and Efluelda® relative vaccine effectiveNess – 2021-22 season in France
Hélène Bricout, Sanofi Vaccines, France
Measuring the impact of influenza vaccination using linked observational primary care, hospitalization and mortality data
Marianne Heins, Nivel, The Netherlands
Mathematical modelling and projections, including limitationsscs08
Auditorium 2 - Breakout
SCS
Chair
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands
Lectures
Post-vaccine HAI antibody kinetics are driven by pre-existing immune status
David Hodgson, London School of Hygiene and Tropical Medicine, United Kingdom
Global Estimates of Influenza-associated Respiratory Hospitalization for 2008-2019 from the InfluEnza BurdEn, Global Project (IcEBErG)
A Danielle Iuliano, Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
Reconstructing household transmission dynamics to estimate the infectiousness of asymptomatic influenza virus infections
Tim Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. (China); Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region. (China)
Public Health and Economic Benefits of Seasonal Influenza Vaccination in Risk Groups in France, Italy, Spain and the United Kingdom: State of play and Perspectives
Thierry Rigoine de Fougerolles, CVA, Paris, France
Population-Level Benefits of Increasing Influenza Vaccination Uptake among Italian Older Adults: Results from a Granular Panel Model
Alexander Domnich, Ospedale Policlinico San Martino IRCCS, Italy
ESWI Symposium: RSV Looking towards the futurespi07
Auditorium 3 - Breakout
SPI
Chairs
Peter Openshaw
Peter Openshaw, ESWI Board Member, Imperial College, The United Kingdom
Stefania Maggi
Stefania Maggi, ESWI Board member, National Research Council of Italy, Italy
Lectures
How 8 years of public-private partnerships have prepared Europe for RSV immunisation
Charlotte Vernhes, Sanofi, France
Epidemiology and surveillance
John Paget, Nivel, The Netherlands
Potential economic benefit of RSV prevention in Europe
Maarten Postma, University of Groningen, The Netherlands
RSV Vaccines: what's in the pipeline?
Joanne Wildenbeest, UMC Utrecht, The Netherlands
12:30 - 14:00
Lunchlun02
Exhibition hall
From the Young to the Young-at-Heart: Pushing for better Influenza protection for all - Satellite Symposium organised by CSL Seqirussat06
Auditorium 1 - Plenary Hall
Chair
Odile Launay
Odile Launay, Université Paris Cité and Cochin Hospital, France
Lectures
Welcome and introduction
Odile Launay, Aphp, France
Examining the impact of egg-based adaptations on imprinting/original antigenic sin
Matthew Miller, Michael G. DeGroote Institute for Infectious Disease Research, Canada
Influenza vaccination: implications of immunosenescence and comorbidities
Graham Pawelec, University of Tübingen, Germany
In peace, prepare for battle: critical importance of active pandemic preparedness
Colin Russell, Academic Medical Center, The Netherlands
Panel discussion with audience Q&A
Odile Launay, Aphp, France
14:10 - 15:45
Parallel sessions
Future vaccination strategiesscs09
Auditorium 1 - Plenary Hall
SCS
Chairs
Florian Krammer
Florian Krammer, ESWI Board member, Icahn School of Medicine at Mount Sinai, United States of America
Irene Gonzalez
Irene Gonzalez, Icahn School of Medicine Mount Sinai, United States of America
Lectures
Prior SARS-CoV-2 infection enhances Spike-specific humoral and T-cell response shortly after mRNA vaccination but has a transitory effect on long-term immunity
Vanessa Silva-Moraes, Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, United States
Cellular responses to past H2N2 influenza virus: a matter of antigen exposure or age?
Afshin Zariri, RIVM, Netherlands, The
Extended Delivery of Influenza Virus Vaccine Improves the Quantity and Quality of the Induced Immune Responses in Mice
Martin Beukema, University Medical Center Groningen, Netherlands, The
Influenza pre-immune ferrets vaccinated with computationally optimized recombinant HA proteins generate sero-protective antibody responses against H1N1 and H3N2 viruses from the last decade.
James Allen, Cleveland Clinic, United States of America
Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against RSV: Results from a Phase 1 Randomized Clinical Trial in Older Adults Including a 12-month Booster Injection
Sonia K. Stoszek, Moderna, Inc., Cambridge, MA, USA
Long COVID and other long term effects of ARVI infectionsscs10
Auditorium 2 - Breakout
SCS
Chair
Rebecca Cox
Rebecca Cox, University of Bergen, Norway
Lectures
Long-term fatigue after SARS-CoV-2 infection in the Netherlands: a prospective cohort study (VASCO)
Anne J. Huiberts, Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), the Netherlands
Reduction in long-COVID symptoms and symptom severity in vaccinated compared to unvaccinated adults
Hannah Maier, University of Michigan, United States of America
A Bayesian network model for estimating risk of long COVID
Jane E. Sinclair, School of Chemistry and Molecular Biosciences, The University of Queensland, Australia
Vaccination status and differences in clinical outcomes and long COVID symptoms among patients hospitalized with COVID-19: the WHF Covid-19 Long-term Study
Kalyani Nikhare, Public Health Foundation of India, India
Post COVID-19 condition in children and adolescents after delta infection and omicron reinfection
Rebecca Jane Cox, University of Bergen - Influenza Centre, Department of Clinical Science
Intervention strategies for the management of ARVIspi05
Auditorium 3 - Breakout
SPI
Chair
Nabil Jamshed
Nabil Jamshed, European Health Management Association (EHMA), The United Kingdom
Lectures
The diagnostic testing requirements for efficient mass distribution and use of antivirals
Alvin Han, Amsterdam University Medical Center, The Netherlands
The state of the art of antivirals in ARVI, their current role and their potential
Michael Ison, NIAID/NIH, United States of America
Health policy and social implications of the vaccination campaigns aimed at preventing ARVI outbreaks
Federica Morandi, High School of Economics and Management of Healthcare Systems (ALTEMS), Italy
Round table discussion
Nabil Jamshed, European Health Management Association (EHMA), United Kingdom
15:45 - 16:15
Coffee Breakcof04
Exhibition hall
Poster Peek - Virtualpeek04
Poster Peak - web platform
Chair
Debby  Van Riel
Debby Van Riel, Erasmus MC, The Netherlands

Highly pathogenic avian influenza A virus (HPAIV) H5N1 infection in two European grey seals (Halichoerus grypus) with encephalitis
Monica Mirolo, University of veterinary medicine hannover, foundation, Germany

The response of Adult and Paediatric Nasal Epithelial cells to Influenza A Viral Infection
Neve Collins, University of Queensland, Australia

In vitro and in vivo differences in neurovirulence between D614G, Delta and Omicron BA.1 SARS-CoV-2 variants
Lisa Bauer, Erasmus MC, The Netherlands

16:15 - 18:00
Parallel sessions
Virus structure and replicationscs11
Auditorium 2 - Breakout
SCS
Chairs
Ed Hutchinson
Ed Hutchinson, ESWI Board member, University of Glasgow, The United Kingdom
Jenna Guthmiller
Jenna Guthmiller, University of Colorado Anschutz School of Medicine, United States of America
Lectures
Identifying determinants of IAV infection success using real-time single vRNP imaging
Huib Rabouw, Hubrecht Institute, Netherlands, The
Transient stem-loop RNA structures and purine-rich sequences at the H5 hemagglutinin cleavage site drive duplications by the influenza polymerase: a potential explanation of highly pathogenic avian influenza genesis
Mathis Funk, Erasmus MC, Netherlands, The
Integrative modelling of influenza A virus particles
Edward Hutchinson, University of Glasgow, United Kingdom
Cryptic proteins translated from defective viral genomes are dominant negative inhibitors of the influenza viral polymerase
Andrew Mehle, Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, USA
Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans
Zoé Schmal, Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, Hamburg, Germany
Antiviral and immune therapyscs12
Auditorium 1 - Plenary Hall
SCS
Chair
Michael Ison
Michael Ison, NIAID/NIH, United States of America
Lectures
Uncovering the potential of influenza A virus neuraminidase-targeted nanobodies: enhancing affinity, breadth, and functionality through multivalency
Mirte Pascha, Utrecht University, The Netherlands
In vitro and in vivo characterization of SARS-CoV-2 resistance to nirmatrelvir
Seiya Yamayoshi, Division of Virology, Institute of Medical Science, University of Tokyo, Japan; International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Japan
A Novel SARS-CoV-2 Inhibitor Targeting the Membrane Protein With Activity in a SCID Mouse Model
Manon Laporte, KU Leuven, Rega Institute, Belgium
In vivo evaluation of a spray-dried entry inhibitor against influenza using an in-house aerosol generator for the pulmonary administration of powder formulations to mice.
Rick Heida, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Triple targeting of SARS-CoV-2 spike protein using ultrapotent neutralizing single-domain antibodies that bind unique and conserved epitopes in the S1 and S2 subunit of the spike
Viki Bockstal, Exevir, Belgium
Communication: Raising awareness on the burden of diseasespi06
Auditorium 3 - Breakout
SPI
Chair
Stefania Maggi
Stefania Maggi, ESWI Board member, National Research Council of Italy, Italy
Lectures
Communication techniques and strategies
Emilie Karafillakis, Vaccine Confidence Project, United Kingdom
Perception and cognitive aspects of raising awareness
Frederic Bouder, University of Stavanger, Norway
Facts and fallacies about vaccination, an independent information document about vaccination in healthcare
Ted van Essen, ESWI, The Netherlands
Panel and audience discussion
Stefania Maggi, National Research Council of Italy, ESWI Board Member, Italy
18:15 - 19:45
Managing influenza infections in a new era of healthcare: the role of antivirals in reducing transmission - Satellite Symposium organised by Rochesat07
Auditorium 1 - Plenary Hall
Chair
Frederick Hayden
Frederick Hayden, University of Virginia School of Medicine, United States of America
Lectures
Welcome and introduction
Frederick Hayden, University of Virginia School of Medicine, United States of America
Latest updates and challenges in the field of influenza
Jordi Rello, Universitat Interncional de Catalunya, Spain
Impact of viral load reduction on influenza transmission
Ben Cowling, University of Hong Kong, Hong Kong S.A.R. (China)
Modelling the benefits of reducing influenza transmission
Lauren Meyers, The University of Texas at Austin, United States of America
Summary of key points
Frederick Hayden, University of Virginia School of Medicine, United States of America
Q&A and close with all faculty
Frederick Hayden, University of Virginia School of Medicine, United States of America
20:00 - 22:00
Farewell dinnerrec02
Exhibition hall
Wednesday 20 September 2023
08:00 - 09:00
Driving towards toddler protection in RSV: A role for targeting mucosal immunity - Satellite Symposium organised by Sanofisat08
Auditorium 1 - Plenary Hall
Chair
Lorenzo Bertizzolo
Lorenzo Bertizzolo, Sanofi, France
Lectures
Welcome and introductions
Lorenzo Bertizzolo, Sanofi Pasteur, France
The toll on toddlers: the forgotten population burdened by RSV
Terho Heikkinen, University of Turku, Finland, Finland
Utilising the frontline defence: the potential of mucosal immunity for RSV protection
Peter Openshaw, ESWI Board member, Imperial College London, United Kingdom
Discussion and Q&A session
Lorenzo Bertizzolo, Sanofi Pasteur, France
Session close
Lorenzo Bertizzolo, Sanofi Pasteur, France
09:15 - 10:15
Plenary session dedicated to the work of Early Career Scientistsscs13
Auditorium 1 - Plenary Hall
SCS
Chairs
Debby  Van Riel
Debby Van Riel, Erasmus MC, The Netherlands
Ab Osterhaus
Ab Osterhaus, ESWI Chair, TiHO, Germany
Colin Russell
Colin Russell, ESWI Board member, Academic Medical Center, University of Amsterdam, The Netherlands
Lectures
The Claude Hannoun prize for Best Body of Work
Albert Osterhaus, ESWI, TiHo, Germany
Dynamics of CD8+ T cell immunity to circulating and pandemic viruses
Carolien van de Sandt, The University of Melbourne at the Peter Doherty Institute, Australia
Young Scientist Vaccine Innovation Award
Sankarasubramanian {Raja} Rajaram, CSL Seqirus, United Kingdom
The co-evolution of influenza viruses and the antibodies that neutralize them
Jenna Guthmiller, University of Colorado Anschutz Medical Campus, United States of America
The Award on Diversity Equity and Inclusion
Meral Akcay, Sanofi Pasteur, France
10:15 - 10:45
Coffee Breakcof05
Exhibition hall
10:45 - 12:20
Parallel sessions
Clinical manifestations, burden of disease and managementscs14
Auditorium 1 - Plenary Hall
SCS
Chairs
Marco Goeijenbier
Marco Goeijenbier, ESWI Board member, Spaarne Hospital, The Netherlands
Antonia Ho
Antonia Ho, University of Glasgow, The United Kingdom
Lectures
Host transcriptomics and machine learning provide a novel forward predictive model for bacterial infections in patients with COVID-19
Kirsty Short, University of Queensland, Australia
Type 2 Diabetes and seasonal influenza – an ominous combination?
Elin Allansson Kjölhede, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden
Global influenza-associated respiratory hospitalization estimates: a preliminary comparisons of different approaches
Yun Lin, University of Hong Kong, Hong Kong S.A.R. (China)
Incidence of influenza-associated acute respiratory illness hospitalizations in Bangladesh: 2010-2019
Fahmida Chowdhury, International Centre for Diarrhoeal Disease and Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Leveraging Real-World Evidence to Inform RSV-LRTD and Severe RSV-LRTD Case Definitions for a Pivotal Phase 2/3 Clinical Trial of the mRNA-1345 RSV Vaccine Candidate in Adults Aged ≥60 Years
Catherine A Panozzo, Moderna, Inc., Cambridge, MA, USA (*Employees of Moderna, Inc. at the time of study conduct)
Threats from the animal worldscs15
Auditorium 2 - Breakout
SCS
Chair
Ron Fouchier
Ron Fouchier, Erasmus MC, The Netherlands
Lectures
HPAI H5 viruses in wild migratory birds in the Netherlands
Ron Fouchier, Erasmus MC, Netherlands, The
Candidate mutations involved in Influenza A virus host-switching events.
Rocío Leiva Rebollo, Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
High number of HPAI H5 Virus Infections and Antibodies in Wild Carnivores in the Netherlands, 2020-2022
Reina Sikkema, ErasmusMC, Netherlands, The
The Azov-Black Sea region is a hot-spot in Europe for early detection of H5 HPAI viruses in clinically healthy wild birds
Denys Muzyka, NSC Institute of Experimental and Clinical Veterinary Medicine, Kharkiv, Ukraine
Avian influenza virus infections in marine mammals, another reason for concern?
Monica Mirolo, Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany
Global health perspectives on acute respiratory virus disease and how to ensure an equitable response/access to vaccines and therapyspi04
Auditorium 3 - Breakout
SPI
Chair
Ann Moen
Ann Moen, Centers for Disease Control and Prevention, retired, United States of America
Lectures
Cascading failures in Covid 19 Vaccine Equity: an overview
David Addiss, Task Force for Global Health, United States of America
Supporting equitable capacity building in countries to support delivery of vaccines and therapeutics
Alfred Douba, Felix Houphouet-Boigny University, Côte d'Ivoire
Equitable production capacity in countries with lessons from GAP and the mRNA vaccine hub project
Christopher Chadwick, World Health Organization, Switzerland
Efficiency and equity in genomic surveillance of respiratory viruses
Simon P.J. De Jong, Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Netherlands, The
12:25 - 13:55
Lunchlun03
Exhibition hall
Clearing the fog: a path towards long COVID prevention? - Satellite Symposium organised by Shionogisat09
Auditorium 1 - Plenary Hall
Chair
Amitava Banerjee
Amitava Banerjee, University College London, The United Kingdom
Lectures
Welcome and introduction
Amitava Banerjee, University College London, United Kingdom
Clearing the Fog: What is long COVID?
Daniel Altmann, Imperial College, United Kingdom
Delivering care and improving healthcare provision for people with long COVID
Melissa Heightman, UCLH, United Kingdom
Towards prevention and cure: How are we researching Long COVID?
Amitava Banerjee, University College London, United Kingdom
Panel discussion and Q&A with all faculty
Amitava Banerjee, University College London, United Kingdom
Reflection points & meeting close
Amitava Banerjee, University College London, United Kingdom
14:05 - 15:35
Expert insights on RSV in Older Adults: disease burden, management, and prevention - Satellite Symposium organised by GSKsat10
Auditorium 1 - Plenary Hall
Chair
Javier Diez-Domingo
Javier Diez-Domingo, FISABIO, Spain

PM-GBL-RSA-AGND-230002 07/2023

©2023 GSK group of companies or its licensor GlaxoSmithKline

Biologicals SA. Rixensart, Belgium

Lectures
Welcome and introduction
Javier Dièz-Domingo, FISABIO, Spain
RSV disease in older adults: Overview of RSV epidemiology and burden in older adults including those with underlying comorbidities
Albert Osterhaus, ESWI, TiHo, Germany
Entering a new era of RSV prevention: Overview of clinical data for RSV vaccine for older adults
Javier Dièz-Domingo, FISABIO, Spain
Challenges of vaccinating older adults
Stefania Maggi, National Research Council of Italy, Italy
Panel discussion: Implementation considerations and gaps to be addressed to best protect older adults from RSV in the new era of RSV prevention
Javier Dièz-Domingo, FISABIO, Spain
Q&A and closing remarks
Javier Dièz-Domingo, FISABIO, Spain
15:45 - 17:15
Late Breakers: novel and outstanding new discoveriesscs16
Auditorium 1 - Plenary Hall
SCS
Chairs
Kirsty Short
Kirsty Short, ESWI Associate Member, University of Queensland, Australia
George Kassianos
George Kassianos, ESWI Board Member, Occupational Health Physician, The United Kingdom
Lectures
Efficacy of an Unadjuvanted Maternal Respiratory Syncytial Virus (RSV) Prefusion F Protein-Based Vaccine (RSVPreF3-Mat) in Infants: Interim Analysis up to 6 Months Post-Birth
Marta Picciolato, GSK, Wavre, Belgium
NDV-HXP-S, a COVID-19 vaccine to boost mucosal immunity.
Sean Liu, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Human anti-N1 NA monoclonal antibodies binding to the underside of the globular head broadly inhibit HxN1 viruses in vitro and in vivo
Lena Hansen, University of Colorado, United States of America; Influenza Centre, Department of Clinical Science, University of Bergen, Norway
Healthy adults possess cross-reactive neuraminidase inhibition antibodies to an A(H5N1) clade 2.3.4.4b avian influenza virus A/Black Faced Spoonbill/Hong Kong/AFCD-HKU-22-21429-01012/2022
Pavithra Daulagala, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
Convergent Recognition of Antigenic Supersites Within Influenza Hemagglutinin Stem in Nonhuman Primates
Maya Sangesland, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, MD 20892, USA.
17:15 - 17:30
The Influenza B/Yamagata lineage appears to become extinct: implications for quadrivalent influenza vaccines?spi08
Auditorium 1 - Plenary Hall
SPI
Chair
Ab Osterhaus
Ab Osterhaus, ESWI Chair, TiHO, Germany

Ben Cowling, University of Hong Kong, Hong Kong S.A.R. 

Wenqing Zhang, World Health Organization, Switzerland

17:30 - 18:00
Plenary Closing and Award Ceremonyple04
Auditorium 1 - Plenary Hall

Highlights of the conference from the Chairs

Ab Osterhaus, ESWI Chair, TiHo, Germany

Colin Russell, ESWI Board Member, Academic Medical Center, The Netherlands

Marco Goeijenbier, ESWI Board Member, Spaarne Gasthuis,The Netherlands

Presentation of the ESWI lifetime achievement award

Ab Osterhaus, ESWI Chair, TiHo, Germany

Colin Russell, ESWI Board Member, Academic Medical Center, The Netherlands

Announcement ESWI Conference 2025

Colin Russell, ESWI Board Member, Academic Medical Center, The Netherlands